tinidazole has been researched along with Infections, Helicobacter in 205 studies
Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.
tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin-tinidazole-based triple therapy was highly effective and safe as a first-line regimen in Indian patients with gastroduodenal ulcer disease associated with H." | 9.17 | Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Saif, R; Shah, A; Shoukat, A; Sodhi, JS; Teli, F; Yattoo, GN; Zargar, SA, 2013) |
| "Omeprazole, clarithromycin and tinidazole for 7 days heals active duodenal ulcer and eradicates H." | 9.10 | Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. ( Angelucci, D; Cellini, L; Marzio, L, 2003) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 9.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 9.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| "Lansoprazole 30 mg, amoxicillin 1000 mg, and tinidazole 500 mg were given twice daily to 39 peptic ulcer patients (26 duodenal and 13 gastric ulcer, mean age 52." | 9.09 | Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease. ( Gonlachanvit, S; Kladchareon, N; Kullavanijaya, P; Mahachai, V, 2000) |
| "To evaluate the efficacy of 1-week triple therapy with omeprazole, clarithromycin,and tinidazole (OCT) in Helicobacter pylori-positive older patients with dyspepsia." | 9.09 | The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. ( Arber, N; Brill, S; Halpern, Z; Konikoff, FM; Moshkowitz, M; Reif, S, 1999) |
| "Patients (n = 144) with proven duodenal ulcer (DU) were randomized to one of the three following regimens: group A, omeprazole (2 x 40 mg) plus amoxycillin (4 x 500 mg) for 2 wk; group B, triple therapy: bismuth nitrate (4 x 375 mg) plus metronidazole (4 x 250 mg) and tetracycline (4 x 500 mg) daily for 2 wk and ranitidine (150 mg) for the first week and bismuth nitrate (4 x 375 mg) alone for a further 2 wk; group C, omeprazole (20 mg) plus amoxycillin (4 x 500 mg) and tinidazole (2 x 500 mg) for 2 wk." | 9.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| "Duodenal ulcer healing rates at 4 weeks were 96% after both lansoprazole with amoxycillin, and lansoprazole with triple therapy, and 97% after lansoprazole alone." | 9.08 | Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. ( Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F, 1996) |
| " We attempted to investigate the role of clarithromycin with tinidazole on Helicobacter pylori-related gastritis from the aspects of clinical effect and COX-2 expression." | 8.02 | Clinical Effect of Clarithromycin Combined with Tinidazole on Helicobacter pylori-Related Gastritis and Its Influence on COX-2 Expression. ( He, C; Kong, F; Liu, Y; Wang, K; Zhao, W; Zhu, X, 2021) |
| "Levofloxacin-tinidazole-based triple therapy was highly effective and safe as a first-line regimen in Indian patients with gastroduodenal ulcer disease associated with H." | 5.17 | Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Saif, R; Shah, A; Shoukat, A; Sodhi, JS; Teli, F; Yattoo, GN; Zargar, SA, 2013) |
| "Forty-eight patients with hyperplastic gastric polyps (3-10 mm in diameter) infected with H pylori were randomly assigned to a treatment group (n = 24) which received proton-pump inhibitor (omeprazole or lansoprazole), clarithromycin, bismuth citrate and tinidazole, and a control group (n = 24) which received protective agent of gastric mucosa (tepretone)." | 5.12 | Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. ( Chen, JY; Ji, F; Li, YM; Ning, JW; Wang, QY; Wang, ZW, 2006) |
| "The study was performed in 137 patients with peptic ulcer who had undergone a 7-day course of eradication treatment with one of two sets of drugs: 1, omeprazole, amoxicillin, and tinidazole or 2, omeprazole, clarithromycin, and tinidazole." | 5.12 | Oral health status and oral hygiene practices of patients with peptic ulcer and how these affect Helicobacter pylori eradication from the stomach. ( Bucki, R; Gotebiewska, M; Kemona, A; Namiot, DB; Namiot, Z, 2007) |
| "The purpose of this study was to compare the efficacy of tinidazole- versus clarithromycin-based triple regimens for eradication of Helicobacter pylori in North Indian patients of peptic ulcer disease, and to correlate the outcome with in vitro antibiotic susceptibility." | 5.11 | Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. ( Ahuja, V; Bal, C; Bhatia, V; Das, B; Sharma, MP, 2004) |
| "A randomized, placebo-controlled, treatment trial in Vietnam allocated 296 Helicobacter pylori-infected patients with peptic ulcer of >or= 5 mm to one of three regimens: (i) twice-daily: lansoprazole 30 mg, clarithromycin 250 mg and tinidazole 500 mg; (ii) once-daily: lansoprazole 60 mg, clarithromycin 500 mg and tinidazole 1000 mg; (iii) once-daily: placebo, clarithromycin 500 mg and tinidazole 1000 mg." | 5.10 | Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. ( Björkman, A; Granström, M; Hoang, TT; Phung, DC; Sörberg, M; Wheeldon, TU, 2003) |
| "Omeprazole, clarithromycin and tinidazole for 7 days heals active duodenal ulcer and eradicates H." | 5.10 | Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. ( Angelucci, D; Cellini, L; Marzio, L, 2003) |
| "To determine the value of Helicobacter pylori (Hp) serology in diagnosis of active Hp infection in patients with documented duodenal ulcer (DU) and to directly compare the efficacy and side-effects profiles of metronidazole or tinidazole in a triple therapy regimen to eradicate active Hp infection." | 5.10 | Diagnosis and eradication of Helicobacter pylori in patients with duodenal ulceration in the community. ( Abbas, AB; Abbas, SZ; Crawshaw, A; Dalton, HR; English, J; McGovern, D; Shaw, S; Vivian, G, 2003) |
| "In a randomized, multicentre, prospective study, a total of 352 patients with duodenal ulcer or non-ulcer dyspepsia were randomly divided into three groups according to the administered regimen: OAC250 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 250 mg), OAC500 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg) and OTC group (omeprazole, 20 mg, tinidazole, 500 mg, and clarithromycin, 500 mg)." | 5.10 | Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. ( Ahn, DS; Choi, IJ; Choi, KW; Chung, IS; Chung, JM; Hong, WS; Jung, HC; Kim, JH; Lee, SI; Rew, JS; Rhee, JC; Yang, US, 2002) |
| "A total of 120 patients with peptic ulcer and non-ulcer dyspepsia were randomly assigned to a 2-week course of either: famotidine 40 mg twice a day, amoxycillin 1 g twice a day and tinidazole 500 mg twice a day (FAT group; n = 60); or omeprazole 20 mg twice a day, amoxycillin 1 g twice a day and tinidazole 500 mg twice a day (OAT group; n = 60)." | 5.09 | Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection. ( Changchien, CS; Chen, JJ; Hsu, CC; Hu, TH; Lu, SN, 2001) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 5.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| "Lansoprazole 30 mg, amoxicillin 1000 mg, and tinidazole 500 mg were given twice daily to 39 peptic ulcer patients (26 duodenal and 13 gastric ulcer, mean age 52." | 5.09 | Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease. ( Gonlachanvit, S; Kladchareon, N; Kullavanijaya, P; Mahachai, V, 2000) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 5.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| "To evaluate the efficacy of 1-week triple therapy with omeprazole, clarithromycin,and tinidazole (OCT) in Helicobacter pylori-positive older patients with dyspepsia." | 5.09 | The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. ( Arber, N; Brill, S; Halpern, Z; Konikoff, FM; Moshkowitz, M; Reif, S, 1999) |
| "Duodenal ulcer healing rates at 4 weeks were 96% after both lansoprazole with amoxycillin, and lansoprazole with triple therapy, and 97% after lansoprazole alone." | 5.08 | Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. ( Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F, 1996) |
| "Patients (n = 144) with proven duodenal ulcer (DU) were randomized to one of the three following regimens: group A, omeprazole (2 x 40 mg) plus amoxycillin (4 x 500 mg) for 2 wk; group B, triple therapy: bismuth nitrate (4 x 375 mg) plus metronidazole (4 x 250 mg) and tetracycline (4 x 500 mg) daily for 2 wk and ranitidine (150 mg) for the first week and bismuth nitrate (4 x 375 mg) alone for a further 2 wk; group C, omeprazole (20 mg) plus amoxycillin (4 x 500 mg) and tinidazole (2 x 500 mg) for 2 wk." | 5.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| "In a prospective study, 113 patients with peptic ulcer (n = 36) or non-ulcer dyspepsia (n = 77) were randomized to receive 1-wk treatment, composed of omeprazole 20 mg b." | 5.08 | Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. ( Attili, AF; Diana, F; Pugliano, F; Rinaldi, V; Zullo, A, 1997) |
| "During a period of 1 year 152 patients with gastric ulcers were randomly assigned to one of two treatment regimens: omeprazole 20 mg daily in the morning for 8 weeks (74 patients), or bismuth subsalicylate 600 mg three times daily for 8 weeks combined with 500 mg amoxicillin twice daily and 1000 mg tinidazole twice daily for the first 10 days (triple therapy) (78 patients)." | 5.08 | Cure of gastric ulcer disease after cure of Helicobacter pylori infection--German Gastric Ulcer Study. ( Bästlein, E; Bayerdörffer, E; Bolle, KH; Hatz, R; Heldwein, W; Höchter, W; Klann, H; Lehn, N; Mannes, GA; Meining, A; Miehlke, S; Ruckdeschel, G; Simon, T; Sommer, A; Stolte, M; Weingart, J, 1996) |
| "Forty-three patients with active duodenal ulcers diagnosed at endoscopy were enrolled to receive either 1 g of sucralfate four times daily for 30 days, 500 mg of tetracycline four times daily, and 500 mg of tinidazol three times daily, for 10 days (group A; n = 23) or 150 mg of ranitidine twice daily for 30 days (group B; n = 20)." | 5.07 | Triple therapy with sucralfate is not effective in eradicating Helicobacter pylori and does not reduce duodenal ulcer relapse rates. ( De Nucci, G; Ferraz, JG; Magalhães, AF; Pedrazzoli, J; Trevisan, M, 1994) |
| "Thirty two patients with Helicobacter pylori positive duodenal ulcers resistant to treatment were randomly assigned to 4 weeks' treatment with sucralphate 4 g/day or colloidal bismuth subcitrate 480 mg/day plus amoxycillin from days 1 to 7 and tinidazole from days 8 to 14." | 5.07 | Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. ( Bianchi Porro, G; Lazzaroni, M; Parente, F, 1993) |
| " In triple therapy, two studies used the same regimen in nonulcer dyspepsia patients: lansoprazole 30 mg/day for 2 weeks, amoxicillin 2 g/day for 2 weeks, and tinidazole 1 g/day for 2 weeks." | 4.78 | Effect of lansoprazole on Helicobacter pylori. ( Lamouliatte, H, 1993) |
| " We attempted to investigate the role of clarithromycin with tinidazole on Helicobacter pylori-related gastritis from the aspects of clinical effect and COX-2 expression." | 4.02 | Clinical Effect of Clarithromycin Combined with Tinidazole on Helicobacter pylori-Related Gastritis and Its Influence on COX-2 Expression. ( He, C; Kong, F; Liu, Y; Wang, K; Zhao, W; Zhu, X, 2021) |
| " pylori strain (34 duodenal ulcer and 37 nonulcer dyspepsia) received omeprazole 40 mg o." | 3.70 | Weekend therapy for the treatment of Helicobacter pylori infection. ( Agosti, R; Bocus, P; Caletti, G; Grigioni, WF; Mazzoni, C; Orcioni, GF; Paparo, GF; Poli, L; Sottili, S; Togliani, T; Tucci, A, 1998) |
| " pylori-infected patients with duodenal ulcer were treated with either omeprazole or famotidine plus two antibiotics for 2 wk." | 3.70 | The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. ( Acevedo, C; Duarte, I; Figueroa, C; Fuster, F; Giancaspero, R; Hola, K; Rollan, A; Schulz, M, 2000) |
| "Sixty three children with dyspepsia (mean age 12 years, range one to 18, M/F 41/22) were Helicobacter pylori positive by histology of gastric antral biopsy specimens and were treated with a six week course of amoxycillin (50 mg/kg) and tinidazole (20 mg/kg)." | 3.68 | Eighteen month follow up of Helicobacter pylori positive children treated with amoxycillin and tinidazole. ( Ainley, C; Altare, F; Ansaldi, N; Holton, J; Oderda, G; Osborn, J; Vaira, D, 1992) |
| "The most common adverse event was the dysgeusia in both the groups." | 2.87 | Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial. ( Shahbazi, S; Vahdat Shariatpanahi, Z, 2018) |
| "pylori and GERD is still unclear." | 2.80 | Effect of Helicobacter pylori eradication on reflux esophagitis therapy: a multi-center randomized control study. ( Chen, MH; Hou, XH; Li, ZS; Lin, SR; Lu, JJ; Meng, LM; Xue, Y; Yan, XE; Zhang, J; Zhou, LY, 2015) |
| "In patients with liver cirrhosis, there is a significant association between H." | 2.76 | Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication. ( Agrawal, A; Chandra, M; Gupta, A; Koowar, S, 2011) |
| "Treatment with metronidazole is as effective as that with tinidazole in terms of efficacy." | 2.73 | Helicobacter pylori eradication: metronidazole or tinidazole? Data from Turin, Italy. ( Astegiano, M; Berrutti, M; De Angelis, C; Fagoonee, S; Leone, N; Morgando, A; Pellicano, R; Repici, A; Rizzetto, M; Saracco, G; Smedile, A, 2008) |
| "Rabeprazole is a proton pump inhibitor which is particularly suitable for use in short-term Helicobacter pylori eradication treatment." | 2.72 | Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. ( Bilardi, C; Dulbecco, P; Giannini, EG; Mamone, M; Mansi, C; Santi, ML; Savarino, V; Testa, R, 2006) |
| "A relapse was defined as moderate or severe reflux symptoms." | 2.70 | Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. ( Axon, AT; Bardhan, C; Brown, L; Dixon, MF; Moayyedi, P; Young, L, 2001) |
| " dosing schedule: RBC 400 mg plus clarithromycin 250 mg and tinidazole 500 mg (RBCCT): RBC 400 mg plus clarithromycin 500 mg and amoxycillin 1 g (RBCCA); RBC 400 mg plus tinidazole 500 mg and amoxycillin 1 g (RBCTA)." | 2.69 | Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. ( Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M, 1998) |
| "All peptic ulcers were healed." | 2.69 | Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. ( De Fanis, C; Di Virgilio, M; Pantaleone, U; Pizzicanella, G; Russo, L; Sciampa, G; Silla, M; Spadaccini, A, 1998) |
| "Fibrinogen changes were also significantly and negatively correlated with age." | 2.69 | Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. ( Arosio, C; Bertinieri, G; Blasi, F; Ceriani, G; Cosentini, R; Mandelli, C; Perondi, R; Ranzi, ML; Tarsia, P; Tien, TV; Torgano, G, 1999) |
| "Thirty-seven per cent of IDDM patients were infected." | 2.69 | Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. ( Armuzzi, A; Gasbarrini, A; Gasbarrini, G; Ghirlanda, G; Ojetti, V; Pitocco, D; Pola, P; Silveri, NG, 2000) |
| "In H." | 2.69 | Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. ( Axon, AT; Bardhan, K; Dixon, MF; Moayyedi, P; Peacock, R; Walan, A; Wason, C, 2000) |
| "Rapid recurrence of H." | 2.68 | Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University. ( Carrazco, J; Checkley, W; Cordero, L; Gilman, RH; Leon-Barua, R; McDonald, J; Ramirez-Ramos, A; Recavarren-Arce, S; Salazar, G; Valdez, Y; Watanabe, J, 1997) |
| " The efficacy of MMF as an immunosuppressant and long-term safety in cats of this dosage regimen is unknown." | 2.61 | ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019) |
| "vaginalis, giardiasis and amebiasis and bacterial vaginosis, malaria, odontogenic infections, anaerobic bacterial infections (pelvic inflammatory disease, diabetic foot), surgical prophylaxis (abdominal and hysterectomy) and Helicobacter pylori eradication." | 2.45 | [Tinidazole: a classical anaerobical drug with multiple potential uses nowadays]. ( Giménez, MJ; Granizo, JJ; Manso, FJ; Pía Rodicio, M, 2009) |
| " Although the dosage of omeprazole in pediatric patients has not been established (no pediatric formulation exists), clarithromycin is available for use in pediatric patients." | 2.40 | Guidelines for the treatment of Helicobacter pylori in the pediatric population. ( Abdel-Rahman, SM; Nahata, MC; Robinson, DM, 1997) |
| "Treatment with omeprazole and amoxycillin could provide both rapid healing of ulcers and eradication of H." | 2.38 | Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. ( Malfertheiner, P, 1993) |
| "The method can be easily implemented in QC studies of the cited drugs in their dosage forms." | 1.72 | RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method. ( Hassib, ST; Mostafa, EA; Sharf, MG; Taha, EA, 2022) |
| "Blepharitis was diagnosed on the basis of findings in ophthalmic and dermatologic examinations." | 1.33 | Prevalence and treatment of Helicobacter pylori in patients with blepharitis. ( Baldi, F; Bilardi, C; Brusati, C; Mastromarino, A; Pascotto, A; Prigione, G; Rebora, A; Saccà, SC; Savarino, V; Venturino, GM, 2006) |
| "In Bangladesh, late recrudescence of H." | 1.31 | Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. ( Ahmad, MM; Arefin, MS; Bardhan, P; Bauerfeind, P; Beglinger, C; Glatz-Krieger, K; Gyr, N; Hasan, M; Hildebrand, P; Khan, AK; Parvin, S; Rahman, A; Rossi, L; Terracciano, L, 2001) |
| "pylori gastritis is equally prevalent in symptomatic and asymptomatic children (31 and 27." | 1.29 | Helicobacter pylori-associated gastritis in Kuwait: endoscopy-based study in symptomatic and asymptomatic children. ( al Nakib, B; Kalaoui, M; Patric, J; Radhakrishnan, S, 1993) |
| "Lansoprazole has a cytotoxic action against this organism, the MIC being 2." | 1.29 | Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication. ( Kawano, S; Murakami, M; Saita, H; Tsuji, S, 1996) |
| "To verify the effectiveness and side-effect profile of an eradicating regimen consisting of omeprazole 20 mg daily for 4 weeks and, during the first week, combination antimicrobial treatment with tinidazole 500 mg b." | 1.29 | High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. ( Carli, G; Dalla Libera, M; Gamberini, S; Gullini, S; Merighi, A; Pazzi, P; Scagliarini, R, 1996) |
| "pylori was detected in dental plaque and in gastric antral and body mucosa in 98%, 67% and 70%, respectively, of 43 consecutive patients with dyspepsia." | 1.28 | Dental plaque: a permanent reservoir of Helicobacter pylori? ( Desai, HG; Gill, HH; Mehta, PR; Prabhu, SR; Shankaran, K, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 75 (36.59) | 18.2507 |
| 2000's | 91 (44.39) | 29.6817 |
| 2010's | 33 (16.10) | 24.3611 |
| 2020's | 6 (2.93) | 2.80 |
| Authors | Studies |
|---|---|
| He, C | 1 |
| Kong, F | 2 |
| Zhu, X | 1 |
| Zhao, W | 2 |
| Liu, Y | 1 |
| Wang, K | 1 |
| Hassib, ST | 1 |
| Taha, EA | 1 |
| Sharf, MG | 1 |
| Mostafa, EA | 1 |
| Shao, Y | 1 |
| Lin, Y | 1 |
| Wang, B | 2 |
| Miao, M | 1 |
| Ye, G | 1 |
| Bobenko, AI | 1 |
| Heller, S | 1 |
| Schmitt, N | 1 |
| Cherdtrakulkiat, R | 1 |
| Lawung, R | 1 |
| Nabu, S | 1 |
| Tantimavanich, S | 1 |
| Sinthupoom, N | 1 |
| Prachayasittikul, S | 1 |
| Prachayasittikul, V | 1 |
| Zhang, B | 1 |
| Wu, C | 1 |
| Zhang, Z | 2 |
| Yan, K | 1 |
| Li, C | 2 |
| Li, Y | 4 |
| Li, L | 3 |
| Zheng, C | 1 |
| Xiao, Y | 1 |
| He, D | 1 |
| Zhao, F | 1 |
| Su, JF | 1 |
| Lun, SM | 1 |
| Hou, YJ | 1 |
| Duan, LJ | 1 |
| Wang, NC | 1 |
| Shen, FF | 1 |
| Zhang, YW | 1 |
| Gao, ZW | 1 |
| Li, J | 5 |
| Du, XJ | 1 |
| Zhou, FY | 1 |
| Yin, Z | 1 |
| Zhu, J | 2 |
| Yan, D | 1 |
| Lou, H | 1 |
| Yu, H | 1 |
| Feng, C | 1 |
| Wang, Z | 1 |
| Wang, Y | 4 |
| Hu, X | 1 |
| Li, Z | 3 |
| Shen, Y | 1 |
| Hu, D | 1 |
| Chen, H | 1 |
| Wu, X | 1 |
| Duan, Y | 1 |
| Zhi, D | 1 |
| Zou, M | 2 |
| Zhao, Z | 1 |
| Zhang, X | 2 |
| Yang, X | 2 |
| Zhang, J | 4 |
| Wang, H | 1 |
| Popović, KJ | 1 |
| Popović, DJ | 1 |
| Miljković, D | 1 |
| Lalošević, D | 1 |
| Čapo, I | 1 |
| Popović, JK | 1 |
| Liu, M | 1 |
| Song, H | 2 |
| Xing, Z | 1 |
| Lu, G | 1 |
| Chen, D | 1 |
| Valentini, AM | 1 |
| Di Pinto, F | 1 |
| Coletta, S | 1 |
| Guerra, V | 1 |
| Armentano, R | 1 |
| Caruso, ML | 1 |
| Gong, J | 1 |
| Wang, N | 1 |
| Bian, L | 1 |
| Wang, M | 1 |
| Ye, M | 1 |
| Wen, N | 1 |
| Fu, M | 1 |
| Fan, W | 1 |
| Meng, Y | 1 |
| Dong, G | 1 |
| Lin, XH | 1 |
| Liu, HH | 1 |
| Gao, DM | 1 |
| Cui, JF | 1 |
| Ren, ZG | 1 |
| Chen, RX | 1 |
| Önal, B | 1 |
| Özen, D | 1 |
| Demir, B | 1 |
| Akkan, AG | 1 |
| Özyazgan, S | 1 |
| Payette, G | 1 |
| Geoffroy, V | 1 |
| Martineau, C | 1 |
| Villemur, R | 1 |
| Jameel, T | 1 |
| Baig, M | 1 |
| Gazzaz, ZJ | 1 |
| Tashkandi, JM | 1 |
| Al Alhareth, NS | 1 |
| Khan, SA | 1 |
| Butt, NS | 1 |
| Wang, J | 2 |
| Geng, Y | 1 |
| Zhang, Y | 3 |
| Wang, X | 2 |
| Liu, J | 2 |
| Basit, A | 1 |
| Miao, T | 1 |
| Liu, W | 1 |
| Jiang, W | 1 |
| Yu, ZY | 1 |
| Wu, L | 2 |
| Qu, B | 1 |
| Sun, JX | 1 |
| Cai, AL | 1 |
| Xie, LM | 1 |
| Groeneveld, J | 1 |
| Ho, SL | 1 |
| Mackensen, A | 1 |
| Mohtadi, M | 1 |
| Laepple, T | 1 |
| Genovesi, S | 1 |
| Nava, E | 1 |
| Bartolucci, C | 1 |
| Severi, S | 1 |
| Vincenti, A | 1 |
| Contaldo, G | 1 |
| Bigatti, G | 1 |
| Ciurlino, D | 1 |
| Bertoli, SV | 1 |
| Slovak, JE | 1 |
| Hwang, JK | 1 |
| Rivera, SM | 1 |
| Villarino, NF | 1 |
| Li, S | 1 |
| Cao, G | 1 |
| Ling, M | 1 |
| Ji, J | 1 |
| Zhao, D | 1 |
| Sha, Y | 1 |
| Gao, X | 1 |
| Liang, C | 2 |
| Guo, Q | 1 |
| Zhou, C | 1 |
| Ma, Z | 1 |
| Xu, J | 1 |
| Wang, C | 1 |
| Xia, X | 1 |
| Jiang, Y | 1 |
| Peng, J | 1 |
| Jia, Z | 1 |
| Li, F | 1 |
| Chen, X | 2 |
| Mo, J | 1 |
| Zhang, S | 2 |
| Li, X | 1 |
| Huang, T | 1 |
| Zhu, Q | 2 |
| Wang, S | 1 |
| Ge, RS | 1 |
| Fortunato, G | 1 |
| Lin, J | 2 |
| Agarwal, PK | 1 |
| Kohen, A | 1 |
| Singh, P | 1 |
| Cheatum, CM | 1 |
| Zhu, D | 1 |
| Hayman, A | 1 |
| Kebede, B | 1 |
| Stewart, I | 1 |
| Chen, G | 1 |
| Frew, R | 1 |
| Guo, X | 1 |
| Gong, Q | 1 |
| Borowiec, J | 1 |
| Han, S | 1 |
| Zhang, M | 1 |
| Willis, M | 1 |
| Kreouzis, T | 1 |
| Yu, K | 1 |
| Chirvony, VS | 1 |
| Sekerbayev, KS | 1 |
| Pérez-Del-Rey, D | 1 |
| Martínez-Pastor, JP | 1 |
| Palazon, F | 1 |
| Boix, PP | 1 |
| Taurbayev, TI | 1 |
| Sessolo, M | 1 |
| Bolink, HJ | 1 |
| Lu, M | 1 |
| Lan, Y | 1 |
| Xiao, J | 1 |
| Song, M | 1 |
| Chen, C | 1 |
| Huang, Q | 1 |
| Cao, Y | 1 |
| Ho, CT | 1 |
| Qi, B | 1 |
| Wang, Q | 1 |
| Zhang, W | 1 |
| Fang, L | 1 |
| Xie, CL | 1 |
| Chen, R | 1 |
| Yang, S | 1 |
| Xia, JM | 1 |
| Zhang, GY | 1 |
| Chen, CH | 1 |
| Yang, XW | 1 |
| Domenech-Ximenos, B | 1 |
| Garza, MS | 1 |
| Prat-González, S | 1 |
| Sepúlveda-Martínez, Á | 1 |
| Crispi, F | 1 |
| Perea, RJ | 1 |
| Garcia-Alvarez, A | 1 |
| Sitges, M | 1 |
| Kalumpha, M | 1 |
| Guyo, U | 1 |
| Zinyama, NP | 1 |
| Vakira, FM | 1 |
| Nyamunda, BC | 1 |
| Varga, M | 1 |
| Drácz, L | 1 |
| Kolbenheyer, E | 1 |
| Varga, F | 1 |
| Patai, ÁV | 1 |
| Solymosi, N | 1 |
| Patai, Á | 1 |
| Kiss, J | 1 |
| Gaál, V | 1 |
| Nyul, Z | 1 |
| Mosdósi, B | 1 |
| Valdez, M | 1 |
| Moosavi, L | 1 |
| Heidari, A | 1 |
| Novakovic-Agopian, T | 1 |
| Kornblith, E | 1 |
| Abrams, G | 1 |
| McQuaid, JR | 1 |
| Posecion, L | 1 |
| Burciaga, J | 1 |
| D'Esposito, M | 1 |
| Chen, AJW | 1 |
| Samy El Gendy, NM | 1 |
| Wesolowska, P | 1 |
| Georg, D | 1 |
| Lechner, W | 1 |
| Kazantsev, P | 1 |
| Bokulic, T | 1 |
| Tedgren, AC | 1 |
| Adolfsson, E | 1 |
| Campos, AM | 1 |
| Alves, VGL | 1 |
| Suming, L | 1 |
| Hao, W | 1 |
| Ekendahl, D | 1 |
| Koniarova, I | 1 |
| Bulski, W | 1 |
| Chelminski, K | 1 |
| Samper, JLA | 1 |
| Vinatha, SP | 1 |
| Rakshit, S | 1 |
| Siri, S | 1 |
| Tomsejm, M | 1 |
| Tenhunen, M | 1 |
| Povall, J | 1 |
| Kry, SF | 1 |
| Followill, DS | 1 |
| Thwaites, DI | 1 |
| Izewska, J | 1 |
| Kang, JH | 1 |
| Yoon, Y | 1 |
| Song, J | 1 |
| Van de Winckel, A | 1 |
| Gauthier, L | 1 |
| Chao, CT | 1 |
| Lee, YH | 1 |
| Li, CM | 1 |
| Han, DS | 1 |
| Huang, JW | 1 |
| Huang, KC | 1 |
| Ni, L | 1 |
| Güttinger, R | 1 |
| Triana, CA | 1 |
| Spingler, B | 1 |
| Baldridge, KK | 1 |
| Patzke, GR | 1 |
| Shen, X | 1 |
| Xie, S | 1 |
| Deng, W | 1 |
| Wu, D | 1 |
| Zhang, Q | 1 |
| Voskamp, BJ | 1 |
| Peelen, MJCS | 1 |
| Ravelli, ACJ | 1 |
| van der Lee, R | 1 |
| Mol, BWJ | 1 |
| Pajkrt, E | 1 |
| Ganzevoort, W | 1 |
| Kazemier, BM | 1 |
| Tibrewala, R | 1 |
| Bahroos, E | 1 |
| Mehrabian, H | 1 |
| Foreman, SC | 1 |
| Link, TM | 1 |
| Pedoia, V | 1 |
| Majumdar, S | 1 |
| Jablonski, CL | 1 |
| Leonard, C | 1 |
| Salo, P | 1 |
| Krawetz, RJ | 1 |
| Yoon, N | 1 |
| Hong, SN | 1 |
| Cho, JG | 1 |
| Jeong, HK | 1 |
| Lee, KH | 1 |
| Park, HW | 1 |
| Barman, S | 1 |
| Konai, MM | 1 |
| Samaddar, S | 1 |
| Haldar, J | 1 |
| Mohamed, HSH | 1 |
| Li, CF | 1 |
| Hu, ZY | 1 |
| Deng, Z | 1 |
| Chen, LH | 1 |
| Su, BL | 1 |
| Chu, K | 1 |
| Liu, YP | 1 |
| Li, YB | 1 |
| Zhang, H | 1 |
| Xu, C | 1 |
| Zou, Z | 1 |
| Wu, Z | 1 |
| Xia, Y | 1 |
| Zhao, P | 1 |
| Wang, HT | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Myint, NPST | 1 |
| Zaw, TT | 1 |
| Sain, K | 1 |
| Waiyan, S | 1 |
| Danta, M | 1 |
| Cooper, D | 1 |
| Aung, NM | 1 |
| Kyi, MM | 1 |
| Hanson, J | 1 |
| Razavizadeh, M | 1 |
| Arj, A | 1 |
| Madani, M | 1 |
| Gilassi, H | 1 |
| Alhalabi, M | 1 |
| Alassi, MW | 1 |
| Alaa Eddin, K | 1 |
| Cheha, K | 1 |
| Fiorini, G | 2 |
| Zullo, A | 16 |
| Saracino, IM | 1 |
| Gatta, L | 3 |
| Pavoni, M | 1 |
| Vaira, D | 8 |
| Tang, D | 1 |
| Yuan, L | 1 |
| Yue, C | 1 |
| Cai, T | 1 |
| Yao, Y | 1 |
| Wang, F | 1 |
| Chen, MJ | 2 |
| Chen, CC | 2 |
| Chen, YN | 1 |
| Fang, YJ | 1 |
| Lin, JT | 1 |
| Wu, MS | 1 |
| Liou, JM | 1 |
| Manfredi, M | 1 |
| Gaiani, F | 1 |
| Kayali, S | 1 |
| Bizzarri, B | 1 |
| Iuliano, S | 1 |
| Minelli, R | 1 |
| Leandro, G | 6 |
| Di Mario, F | 6 |
| De' Angelis, GL | 1 |
| Shahbazi, S | 1 |
| Vahdat Shariatpanahi, Z | 1 |
| Scaccianoce, G | 5 |
| Portincasa, P | 2 |
| De Francesco, V | 13 |
| Vassallo, R | 1 |
| Urban, F | 1 |
| Monica, F | 3 |
| Mogavero, G | 1 |
| Amato, A | 1 |
| Attia, TZ | 1 |
| Yamashita, T | 1 |
| Tsujino, H | 1 |
| Derayea, SM | 1 |
| Tsutsumi, Y | 1 |
| Uno, T | 1 |
| Ruggiero, V | 1 |
| D'Ambrosio, P | 1 |
| Castorani, L | 1 |
| Bonfrate, L | 1 |
| Vannella, L | 1 |
| Hassan, C | 11 |
| Nasa, M | 1 |
| Choksey, A | 1 |
| Phadke, A | 1 |
| Sawant, P | 2 |
| Zhou, L | 1 |
| Chen, M | 1 |
| Hou, X | 1 |
| Song, Z | 1 |
| He, L | 1 |
| Lin, S | 1 |
| Jeon, HK | 1 |
| Kim, GH | 1 |
| Gong, EJ | 1 |
| Yun, SC | 1 |
| Jung, HY | 1 |
| Lim, H | 1 |
| Choi, KS | 1 |
| Ahn, JY | 1 |
| Lee, JH | 1 |
| Kim, DH | 1 |
| Choi, KD | 1 |
| Song, HJ | 1 |
| Lee, GH | 1 |
| Kim, JH | 2 |
| El-Garem, Y | 1 |
| El-Sawy, M | 1 |
| Mostafa, T | 1 |
| Ahmed, S | 1 |
| Atia, NN | 1 |
| Ierardi, E | 10 |
| Giangaspero, A | 1 |
| Losurdo, G | 1 |
| Giorgio, F | 1 |
| Amoruso, A | 3 |
| Di Leo, A | 3 |
| Principi, M | 1 |
| Metanat, HA | 1 |
| Valizadeh, SM | 1 |
| Fakheri, H | 2 |
| Maleki, I | 2 |
| Taghvaei, T | 2 |
| Hosseini, V | 2 |
| Bari, Z | 1 |
| Xue, Y | 1 |
| Zhou, LY | 1 |
| Lin, SR | 1 |
| Hou, XH | 1 |
| Li, ZS | 1 |
| Chen, MH | 1 |
| Yan, XE | 1 |
| Meng, LM | 1 |
| Lu, JJ | 1 |
| Chan, CC | 1 |
| Chien, NH | 1 |
| Lee, CL | 1 |
| Yang, YC | 1 |
| Hung, CS | 1 |
| Tu, TC | 1 |
| Wu, CH | 1 |
| Branquinho, D | 1 |
| Almeida, N | 1 |
| Gregório, C | 1 |
| Cabral, JE | 1 |
| Casela, A | 1 |
| Donato, MM | 1 |
| Tomé, L | 1 |
| Berrutti, M | 1 |
| Pellicano, R | 1 |
| Astegiano, M | 1 |
| Smedile, A | 1 |
| Saracco, G | 1 |
| Morgando, A | 1 |
| De Angelis, C | 1 |
| Repici, A | 1 |
| Fagoonee, S | 1 |
| Leone, N | 1 |
| Rizzetto, M | 1 |
| Tong, JL | 1 |
| Ran, ZH | 1 |
| Shen, J | 1 |
| Xiao, SD | 1 |
| Gwee, KA | 1 |
| Teng, L | 1 |
| Wong, RK | 1 |
| Ho, KY | 1 |
| Sutedja, DS | 1 |
| Yeoh, KG | 1 |
| Granizo, JJ | 1 |
| Pía Rodicio, M | 1 |
| Manso, FJ | 1 |
| Giménez, MJ | 1 |
| Vakil, N | 2 |
| Chaudhry, AS | 1 |
| Kochhar, R | 2 |
| Kohli, KK | 1 |
| Moayyedi, P | 11 |
| Malfertheiner, P | 3 |
| Paoluzi, OA | 1 |
| Visconti, E | 1 |
| Andrei, F | 1 |
| Tosti, C | 1 |
| Lionetti, R | 2 |
| Grasso, E | 1 |
| Ranaldi, R | 1 |
| Stroppa, I | 1 |
| Pallone, F | 2 |
| Dutta, U | 1 |
| Udawat, H | 1 |
| Noor, MT | 1 |
| Sidhu, GS | 1 |
| Vaiphei, K | 1 |
| Singh, K | 1 |
| D'Ercole, C | 1 |
| Albrecht, P | 1 |
| Kotowska, M | 1 |
| Szajewska, H | 1 |
| Agrawal, A | 1 |
| Gupta, A | 1 |
| Chandra, M | 1 |
| Koowar, S | 1 |
| Tursi, A | 7 |
| Elisei, W | 2 |
| Giorgetti, G | 1 |
| Picchio, M | 1 |
| Brandimarte, G | 2 |
| Schmilovitz-Weiss, H | 1 |
| Schmiloviz-Weiss, H | 1 |
| Shalev, T | 1 |
| Chechoulin, Y | 1 |
| Levi, Z | 1 |
| Yishai, R | 1 |
| Sehayek-Shabbat, V | 1 |
| Niv, Y | 2 |
| Shirin, H | 1 |
| Federico, A | 1 |
| Nardone, G | 1 |
| Gravina, AG | 1 |
| Iovene, MR | 1 |
| Miranda, A | 1 |
| Compare, D | 1 |
| Pilloni, PA | 1 |
| Rocco, A | 1 |
| Ricciardiello, L | 3 |
| Marmo, R | 2 |
| Loguercio, C | 1 |
| Romano, M | 2 |
| Choi, HS | 1 |
| Chun, HJ | 1 |
| Park, SH | 1 |
| Keum, B | 1 |
| Seo, YS | 1 |
| Kim, YS | 1 |
| Jeen, YT | 1 |
| Um, SH | 1 |
| Lee, HS | 1 |
| Kim, CD | 1 |
| Ryu, HS | 1 |
| Sereni, G | 1 |
| Azzolini, F | 1 |
| Camellini, L | 1 |
| Formisano, D | 1 |
| Decembrino, F | 1 |
| Iori, V | 4 |
| Tioli, C | 1 |
| Cavina, M | 1 |
| Bedogni, G | 1 |
| Sassatelli, R | 1 |
| Sardarian, H | 1 |
| Mokhtare, M | 1 |
| Shah, A | 1 |
| Javid, G | 1 |
| Zargar, SA | 1 |
| Teli, F | 1 |
| Khan, BA | 1 |
| Yattoo, GN | 1 |
| Gulzar, GM | 1 |
| Sodhi, JS | 1 |
| Khan, MA | 1 |
| Shoukat, A | 1 |
| Saif, R | 1 |
| Faleo, D | 3 |
| Panella, C | 7 |
| Margiotta, M | 2 |
| Ricci, C | 2 |
| Menegatti, M | 1 |
| Tampieri, A | 1 |
| Perna, F | 1 |
| Rinaldi, V | 3 |
| Perri, F | 4 |
| Papadìa, C | 1 |
| Fornari, F | 1 |
| Pilati, S | 1 |
| Mete, LS | 1 |
| Merla, A | 2 |
| Potì, R | 1 |
| Marinone, G | 1 |
| Savioli, A | 1 |
| Campo, SM | 2 |
| Miglioli, M | 2 |
| Morini, S | 9 |
| Anagnostopoulos, GK | 1 |
| Kostopoulos, P | 1 |
| Margantinis, G | 1 |
| Tsiakos, S | 1 |
| Arvanitidis, D | 1 |
| Brzozowski, T | 2 |
| Konturek, PC | 3 |
| Kwiecien, S | 2 |
| Konturek, SJ | 3 |
| Pajdo, R | 1 |
| Drozdowicz, D | 2 |
| Ptak, A | 1 |
| Pawlik, M | 1 |
| Stachura, J | 2 |
| Pawlik, WW | 2 |
| Hahn, EG | 3 |
| Marzio, L | 4 |
| Cellini, L | 3 |
| Angelucci, D | 1 |
| Abbas, SZ | 1 |
| Abbas, AB | 1 |
| Crawshaw, A | 1 |
| Shaw, S | 1 |
| English, J | 1 |
| McGovern, D | 1 |
| Vivian, G | 1 |
| Dalton, HR | 1 |
| Mario, FD | 1 |
| Dal Bo, N | 4 |
| Aragona, G | 3 |
| Moussa, AM | 1 |
| Cavestro, GM | 3 |
| Pilotto, A | 5 |
| Franceschi, M | 2 |
| Rugge, M | 2 |
| Franze, A | 3 |
| Wheeldon, TU | 2 |
| Hoang, TT | 2 |
| Phung, DC | 1 |
| Björkman, A | 1 |
| Granström, M | 3 |
| Sörberg, M | 3 |
| Prónai, L | 1 |
| Tulassay, Z | 1 |
| Kos, M | 1 |
| Zinkiewicz, K | 1 |
| Stefanek, J | 1 |
| Dabrowski, A | 1 |
| Piglionica, D | 3 |
| Festa, V | 2 |
| Barberani, F | 1 |
| Andriulli, A | 3 |
| Neri, M | 1 |
| Milano, A | 1 |
| Laterza, F | 1 |
| Di Bonaventura, G | 1 |
| Piccolomini, R | 1 |
| Caldarella, MP | 1 |
| Balatsinou, C | 1 |
| Lapenna, D | 1 |
| Cuccurullo, F | 1 |
| Toracchio, S | 3 |
| Borody, TJ | 1 |
| Ashman, O | 1 |
| Cavallaro, L | 2 |
| Comparato, G | 2 |
| Herszényi, L | 1 |
| Marangi, S | 1 |
| Burattini, O | 1 |
| Berloco, P | 1 |
| Russo, F | 1 |
| Barone, M | 1 |
| Minenna, MF | 2 |
| Stoppino, V | 3 |
| Francavilla, A | 2 |
| Chaudhary, A | 1 |
| Ahuja, V | 2 |
| Bal, CS | 1 |
| Das, B | 2 |
| Pandey, RM | 1 |
| Sharma, MP | 2 |
| Della Valle, N | 2 |
| Muscatiello, N | 1 |
| Amarapurkar, D | 1 |
| Makesar, M | 1 |
| Amarapurkar, A | 1 |
| Das, HS | 1 |
| Bhatia, V | 1 |
| Bal, C | 1 |
| Namiot, Z | 3 |
| Namiot, DB | 3 |
| Kemona, A | 3 |
| Stasiewicz, J | 1 |
| Pietrini, L | 1 |
| Winn, S | 2 |
| Monno, R | 1 |
| Phuncarg, DC | 1 |
| Nilsson, LE | 1 |
| Oderda, G | 3 |
| Marinello, D | 1 |
| Lerro, P | 1 |
| Kuvidi, M | 1 |
| de'Angelis, GL | 1 |
| Ferzetti, A | 1 |
| Cucchiara, S | 1 |
| Franco, MT | 1 |
| Romano, C | 1 |
| Strisciuglio, P | 1 |
| Pensabene, L | 1 |
| Tindberg, Y | 1 |
| Casswall, TH | 1 |
| Blennow, M | 1 |
| Bengtsson, C | 1 |
| Serpa, J | 1 |
| Lunet, N | 1 |
| Mendes, N | 1 |
| Barros, H | 1 |
| David, L | 1 |
| Manes, G | 2 |
| Balzano, A | 1 |
| de Silva, HA | 1 |
| Hewavisenthi, J | 1 |
| Pathmeswaran, A | 1 |
| Dassanayake, AS | 1 |
| Navaratne, NM | 1 |
| Peiris, R | 1 |
| de Silva, HJ | 1 |
| Capodicasa, S | 1 |
| Soraja, DB | 1 |
| Nista, EC | 1 |
| Candelli, M | 4 |
| Zocco, MA | 2 |
| Cazzato, IA | 1 |
| Cremonini, F | 3 |
| Ojetti, V | 6 |
| Santoro, M | 1 |
| Finizio, R | 1 |
| Pignataro, G | 1 |
| Cammarota, G | 12 |
| Gasbarrini, G | 12 |
| Gasbarrini, A | 10 |
| Ando, T | 1 |
| Minami, M | 1 |
| Mizuno, T | 1 |
| Watanabe, O | 1 |
| Ishiguro, K | 1 |
| Ina, K | 1 |
| Kusugami, K | 1 |
| Nobata, K | 1 |
| Nishiwaki, T | 1 |
| Tsuzuki, T | 1 |
| Shimada, M | 1 |
| El-Omar, E | 1 |
| Goto, H | 1 |
| Francavilla, R | 1 |
| Lionetti, E | 1 |
| Castellaneta, SP | 1 |
| Magistà, AM | 1 |
| Boscarelli, G | 1 |
| Piscitelli, D | 1 |
| Miniello, VL | 1 |
| Cavallo, L | 1 |
| Giannini, EG | 2 |
| Bilardi, C | 3 |
| Dulbecco, P | 2 |
| Mamone, M | 2 |
| Santi, ML | 2 |
| Testa, R | 2 |
| Mansi, C | 2 |
| Savarino, V | 3 |
| Mierzwa, M | 1 |
| Bielanski, W | 2 |
| Saccà, SC | 1 |
| Pascotto, A | 1 |
| Venturino, GM | 1 |
| Prigione, G | 1 |
| Mastromarino, A | 1 |
| Baldi, F | 1 |
| Brusati, C | 1 |
| Rebora, A | 1 |
| Panarese, A | 1 |
| Ji, F | 1 |
| Wang, ZW | 1 |
| Ning, JW | 1 |
| Wang, QY | 1 |
| Chen, JY | 1 |
| Li, YM | 1 |
| Marcon, V | 2 |
| Olivieri, P | 2 |
| Benedetti, E | 2 |
| Orzès, N | 2 |
| Marin, R | 2 |
| Tafner, G | 2 |
| Chilovi, F | 1 |
| De Bastiani, R | 2 |
| Fedrizzi, F | 1 |
| Salvat, MH | 1 |
| Piazzi, L | 1 |
| Valiante, F | 1 |
| Vecchiati, U | 1 |
| Maino, M | 1 |
| Ziemniak, W | 1 |
| Bucki, R | 2 |
| Gotebiewska, M | 1 |
| Giorgetti, GM | 1 |
| Modeo, ME | 1 |
| Aiello, F | 1 |
| Efrati, C | 1 |
| Maconi, G | 3 |
| Cannaviello, C | 1 |
| Ford, AC | 1 |
| Forman, D | 2 |
| Nathan, J | 2 |
| Crocombe, WD | 1 |
| Axon, AT | 10 |
| Shehada, S | 1 |
| Srugo, I | 1 |
| Shaoul, R | 1 |
| Gigliotti, F | 1 |
| Shih, SC | 1 |
| Wang, TE | 1 |
| Chan, YJ | 1 |
| Chen, CJ | 1 |
| Chang, WH | 1 |
| Chen, SJ | 1 |
| Wang, LJ | 1 |
| Cai, JT | 1 |
| Chen, T | 1 |
| Si, JM | 1 |
| Saberi-Firoozi, M | 1 |
| Massarrat, S | 1 |
| Zare, S | 1 |
| Fattahi, M | 1 |
| Javan, A | 1 |
| Etaati, H | 1 |
| Dehbashi, N | 1 |
| Choné, L | 1 |
| Fléjou, JF | 1 |
| Grignon, Y | 1 |
| Bigard, MA | 1 |
| Jaup, BH | 1 |
| Norrby, A | 1 |
| Sobhani, I | 1 |
| Chastang, C | 1 |
| De Korwin, JD | 1 |
| Lamouliatte, H | 2 |
| Mégraud, F | 2 |
| Guerre, J | 1 |
| Elouaer-Blanc, L | 1 |
| Rune, SJ | 1 |
| Goddard, A | 1 |
| Logan, R | 1 |
| Pedrazzoli, J | 1 |
| Magalhães, AF | 1 |
| Ferraz, JG | 1 |
| Trevisan, M | 1 |
| De Nucci, G | 1 |
| Ashorn, M | 1 |
| Ruuska, T | 1 |
| Karikoski, R | 1 |
| Miettinen, A | 1 |
| Mäki, M | 1 |
| Bruel, H | 1 |
| Dabadie, A | 1 |
| Pouedras, P | 1 |
| Gambert, C | 1 |
| Le Gall, E | 1 |
| Jezequel, C | 1 |
| Radhakrishnan, S | 1 |
| al Nakib, B | 1 |
| Kalaoui, M | 1 |
| Patric, J | 1 |
| Bianchi Porro, G | 3 |
| Parente, F | 3 |
| Lazzaroni, M | 1 |
| Sahay, P | 1 |
| Tompkins, DS | 3 |
| Montalto, M | 4 |
| Papa, A | 7 |
| Branca, G | 3 |
| Vecchio, FM | 1 |
| Renzi, C | 1 |
| Verzí, A | 1 |
| Armuzzi, A | 10 |
| Pretolani, S | 1 |
| Fedeli, G | 5 |
| Bazzoli, F | 4 |
| Höök-Nikanne, J | 1 |
| Aho, P | 1 |
| Kärkkäinen, P | 1 |
| Kosunen, TU | 1 |
| Salaspuro, M | 1 |
| Dalla Libera, M | 1 |
| Pazzi, P | 2 |
| Carli, G | 1 |
| Gamberini, S | 2 |
| Scagliarini, R | 2 |
| Merighi, A | 1 |
| Gullini, S | 2 |
| Bargiggia, S | 1 |
| Colombo, E | 1 |
| Sito, E | 1 |
| Kwiecień, N | 1 |
| Baniukiewicz, A | 1 |
| Jedynak, M | 1 |
| Gabryelewicz, A | 2 |
| Bayerdörffer, E | 2 |
| Miehlke, S | 2 |
| Lehn, N | 2 |
| Mannes, GA | 2 |
| Höchter, W | 1 |
| Weingart, J | 1 |
| Klann, H | 1 |
| Sommer, A | 1 |
| Heldwein, W | 1 |
| Hatz, R | 1 |
| Simon, T | 1 |
| Bolle, KH | 1 |
| Bästlein, E | 2 |
| Meining, A | 2 |
| Ruckdeschel, G | 1 |
| Stolte, M | 2 |
| Veneto, G | 1 |
| Cuoco, L | 4 |
| Trua, F | 1 |
| Dammann, HG | 1 |
| Spadaccini, A | 3 |
| De Fanis, C | 2 |
| Sciampa, G | 2 |
| Masciulli, V | 1 |
| Pantaleone, U | 2 |
| Di Virgilio, M | 2 |
| Magnarini, C | 1 |
| Pizzicannella, G | 1 |
| Kawano, S | 1 |
| Murakami, M | 1 |
| Saita, H | 1 |
| Tsuji, S | 1 |
| Moshkowitz, M | 3 |
| Konikoff, FM | 2 |
| Peled, Y | 1 |
| Brill, S | 3 |
| Hallak, A | 1 |
| Tiomny, E | 1 |
| Santo, M | 1 |
| Bujanover, Y | 2 |
| Gilat, T | 1 |
| Drake, IM | 1 |
| Axon, TT | 1 |
| Clarke, AH | 1 |
| Veneto, GM | 1 |
| Cannizzaro, O | 7 |
| Chalmers, DM | 1 |
| Delpre, G | 1 |
| Livni, E | 1 |
| Thijs, JC | 1 |
| Van Zwet, AA | 1 |
| Thijs, WJ | 1 |
| Van der Wouden, EJ | 1 |
| Kooy, A | 1 |
| Robinson, DM | 1 |
| Abdel-Rahman, SM | 1 |
| Nahata, MC | 1 |
| Pugliano, F | 1 |
| Diana, F | 1 |
| Attili, AF | 2 |
| Ramirez-Ramos, A | 1 |
| Gilman, RH | 1 |
| Leon-Barua, R | 1 |
| Recavarren-Arce, S | 1 |
| Watanabe, J | 1 |
| Salazar, G | 1 |
| Checkley, W | 1 |
| McDonald, J | 1 |
| Valdez, Y | 1 |
| Cordero, L | 1 |
| Carrazco, J | 1 |
| Pozzato, P | 3 |
| Seelis, RE | 1 |
| Dohmen, W | 1 |
| Boixeda de Miquel, D | 1 |
| Pérez Mota, A | 1 |
| Alberdi, JM | 1 |
| Pita, L | 1 |
| Galán, JL | 1 |
| García Benito, MD | 1 |
| Crespo, L | 1 |
| Blanco, MA | 1 |
| Güemes, C | 1 |
| Villalgordo, C | 1 |
| Carnicero, JA | 1 |
| Beckford, C | 1 |
| Pérez Muñoz, C | 1 |
| Fernández Velázquez, J | 1 |
| Casanova, A | 1 |
| Ponzetto, A | 1 |
| Boero, M | 2 |
| Bellis, D | 2 |
| Forni, M | 1 |
| Ansaldi, N | 2 |
| Trevisani, L | 2 |
| Sartori, S | 2 |
| Caselli, M | 2 |
| Ruina, M | 2 |
| Verdianelli, G | 2 |
| Abbasciano, V | 2 |
| Ragunathan, PL | 2 |
| Mapstone, N | 2 |
| Tucci, A | 1 |
| Poli, L | 1 |
| Paparo, GF | 1 |
| Bocus, P | 1 |
| Togliani, T | 1 |
| Mazzoni, C | 1 |
| Orcioni, GF | 1 |
| Agosti, R | 1 |
| Grigioni, WF | 1 |
| Sottili, S | 2 |
| Caletti, G | 1 |
| Imbesi, V | 1 |
| Cucino, C | 1 |
| Manzionna, G | 1 |
| Vago, L | 1 |
| Reif, S | 2 |
| Ringel, Y | 1 |
| Arber, N | 2 |
| Halpern, Z | 2 |
| Zagari, M | 2 |
| Varoli, O | 1 |
| Fossi, S | 2 |
| Alampi, G | 1 |
| Nicolini, G | 1 |
| Simoni, P | 1 |
| Roda, A | 1 |
| Roda, E | 2 |
| Clemente, R | 1 |
| Quitadamo, M | 2 |
| Conoscitore, P | 1 |
| Niro, G | 1 |
| Ghoos, Y | 1 |
| Rutgeerts, P | 1 |
| D'Angelo, A | 1 |
| Ederle, A | 1 |
| Gerace, G | 1 |
| Iaquinto, G | 1 |
| Reina, G | 1 |
| Scarpulla, G | 1 |
| Olivieri, A | 1 |
| Tosatto, R | 1 |
| Cianei, R | 1 |
| Fedeli, P | 1 |
| Bardhan, KD | 1 |
| Morton, D | 1 |
| Slater, DN | 1 |
| Perry, MJ | 1 |
| Cherian, P | 1 |
| Jones, RB | 1 |
| Brookes, A | 1 |
| Thompson, M | 1 |
| Morris, P | 1 |
| McCaldin, B | 1 |
| Hashimoto, Y | 1 |
| Matarese, V | 1 |
| Rizzo, C | 1 |
| Cestari, R | 1 |
| Russo, L | 1 |
| Silla, M | 1 |
| Pizzicanella, G | 1 |
| Galvani, F | 1 |
| Torgano, G | 1 |
| Cosentini, R | 1 |
| Mandelli, C | 1 |
| Perondi, R | 1 |
| Blasi, F | 1 |
| Bertinieri, G | 1 |
| Tien, TV | 1 |
| Ceriani, G | 1 |
| Tarsia, P | 1 |
| Arosio, C | 1 |
| Ranzi, ML | 1 |
| Cianci, R | 4 |
| Addolorato, G | 1 |
| Gasbarrini, GB | 1 |
| Delle Cave, M | 1 |
| Vitale, LM | 1 |
| Beneduce, F | 1 |
| Ciamarra, P | 1 |
| Del Vecchio Blanco, C | 1 |
| Neiger, R | 1 |
| Seiler, G | 1 |
| Schmassmann, A | 1 |
| Uygun, A | 1 |
| Ates, Y | 1 |
| Erdil, A | 1 |
| Kadayifci, A | 1 |
| Cetin, C | 1 |
| Gulsen, M | 1 |
| Karaeren, N | 1 |
| Dagalp, K | 1 |
| Pastorelli, A | 3 |
| Gentiloni, N | 1 |
| Pirozzi, G | 2 |
| Canducci, F | 3 |
| Torre, ES | 1 |
| Anti, M | 2 |
| Fadda, G | 1 |
| Pola, P | 4 |
| Rollan, A | 1 |
| Giancaspero, R | 1 |
| Fuster, F | 1 |
| Acevedo, C | 1 |
| Figueroa, C | 1 |
| Hola, K | 1 |
| Schulz, M | 1 |
| Duarte, I | 1 |
| Calvet, X | 2 |
| Titó, L | 1 |
| Comet, R | 1 |
| García, N | 2 |
| Campo, R | 2 |
| Brullet, E | 2 |
| Luman, W | 2 |
| Ling, KL | 2 |
| Ng, HS | 2 |
| Pitocco, D | 1 |
| Silveri, NG | 1 |
| Ghirlanda, G | 1 |
| Kullavanijaya, P | 1 |
| Gonlachanvit, S | 1 |
| Mahachai, V | 1 |
| Kladchareon, N | 1 |
| Meddi, P | 1 |
| Ripani, C | 1 |
| Tomaselli, G | 1 |
| Feltbower, R | 3 |
| Crocombe, W | 2 |
| Mason, S | 3 |
| Atha, P | 1 |
| Brown, J | 3 |
| Dowell, AC | 2 |
| Richards, ID | 2 |
| Mason, J | 2 |
| Battaglia, F | 1 |
| Bottona, E | 1 |
| Caroli, A | 1 |
| Costan-Biedo, F | 1 |
| Germanà, B | 1 |
| Andrea Grassi, S | 1 |
| Madia, D | 1 |
| Ronzani, G | 1 |
| Saggioro, A | 1 |
| Testoni, PA | 2 |
| Bagnolo, F | 1 |
| Santarelli, L | 2 |
| Arancio, F | 1 |
| Calabrese, C | 1 |
| Di Febo, G | 1 |
| Areni, A | 1 |
| Scialpi, C | 1 |
| Biasco, G | 1 |
| Di Campli, E | 1 |
| Cappello, G | 1 |
| Malatesta, MG | 1 |
| Ferri, A | 1 |
| Ciccaglione, AF | 1 |
| Grossi, L | 1 |
| Nijevitch, AA | 1 |
| Farztdinov, KM | 1 |
| Sataev, VU | 1 |
| Katayev, VA | 1 |
| Khusnutdinov, SM | 1 |
| Akhunov, ED | 1 |
| Kazykhanov, NS | 1 |
| Bartolozzi, F | 2 |
| De Lorenzo , A | 1 |
| Fanti, L | 1 |
| Ieri, R | 1 |
| Mezzi, G | 1 |
| Passaretti, S | 1 |
| Guslandi, M | 1 |
| De Lorenzo, A | 1 |
| Wason, C | 1 |
| Peacock, R | 1 |
| Walan, A | 1 |
| Bardhan, K | 1 |
| Dixon, MF | 2 |
| Gené, E | 1 |
| Rathi, P | 1 |
| Gopanpallikar, A | 1 |
| Gołebiewska, M | 1 |
| Luzza, F | 1 |
| Giglio, A | 1 |
| Ciliberto, E | 1 |
| Belmonte, A | 1 |
| Cavaliere, C | 1 |
| Saccà, N | 1 |
| Frandina, C | 1 |
| Fiocca, R | 1 |
| Trimboli, V | 1 |
| Villani, MR | 1 |
| Annese, V | 1 |
| Niro, GA | 1 |
| Lorenzetti, R | 1 |
| Febbraro, I | 1 |
| De Matthaeis, M | 1 |
| Porto, D | 1 |
| Hsu, CC | 1 |
| Chen, JJ | 1 |
| Hu, TH | 1 |
| Lu, SN | 1 |
| Changchien, CS | 1 |
| Ribeiro, JM | 1 |
| Lucas, M | 1 |
| Palhano, MJ | 1 |
| Victorino, RM | 1 |
| Ho, B | 1 |
| Hildebrand, P | 1 |
| Bardhan, P | 1 |
| Rossi, L | 1 |
| Parvin, S | 1 |
| Rahman, A | 1 |
| Arefin, MS | 1 |
| Hasan, M | 1 |
| Ahmad, MM | 1 |
| Glatz-Krieger, K | 1 |
| Terracciano, L | 1 |
| Bauerfeind, P | 1 |
| Beglinger, C | 1 |
| Gyr, N | 1 |
| Khan, AK | 1 |
| Bardhan, C | 1 |
| Young, L | 1 |
| Brown, L | 1 |
| Choi, IJ | 1 |
| Jung, HC | 1 |
| Choi, KW | 1 |
| Ahn, DS | 1 |
| Yang, US | 1 |
| Rew, JS | 1 |
| Lee, SI | 1 |
| Rhee, JC | 1 |
| Chung, IS | 1 |
| Chung, JM | 1 |
| Hong, WS | 1 |
| Duffett, S | 1 |
| Drummond, M | 1 |
| Korotkyĭ, VM | 1 |
| Kolosovych, IV | 1 |
| Di Napoli, A | 1 |
| Petrino, R | 1 |
| Chiandussi, L | 1 |
| Adeyemi, EO | 1 |
| Fadlalla, H | 1 |
| al-Homsi, M | 1 |
| Nnalue, NA | 1 |
| Goodwin, S | 1 |
| Boehme, D | 1 |
| Sim, AJ | 1 |
| Ainley, C | 1 |
| Holton, J | 1 |
| Osborn, J | 1 |
| Altare, F | 1 |
| Desai, HG | 2 |
| Gill, HH | 2 |
| Shankaran, K | 1 |
| Mehta, PR | 2 |
| Prabhu, SR | 2 |
| Ranganathan, S | 1 |
| Kalro, RH | 1 |
| Murti, PK | 1 |
| Morris, A | 1 |
| Lane, M | 1 |
| Hamilton, I | 1 |
| Samarasinghe, D | 1 |
| Ali, MR | 1 |
| Brown, P | 1 |
| Nicholson, G | 1 |
| Iserhard, R | 1 |
| Freise, J | 1 |
| Wagner, S | 1 |
| Bokemeyer, B | 1 |
| Weissbrodt, H | 1 |
| Fritsch, RS | 1 |
| Soudah, B | 1 |
| Schmidt, FW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparing the Efficacy of 14-day Therapy Doxycycline With Bismuth Subsalicylate Versus Levofloxacin With Tinidazole on Rate of Eradication of Helicobacter Pylori Infected Patients on Syrian Population[NCT04348786] | Phase 4 | 78 participants (Actual) | Interventional | 2019-02-01 | Completed | ||
| Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection[NCT02711176] | Phase 4 | 212 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication[NCT02547038] | 352 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| "Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple Hybrid and Concomitant Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance"[NCT01464060] | Phase 4 | 400 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157] | 102 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment[NCT00132171] | Phase 3 | 1,000 participants | Interventional | 2001-01-31 | Completed | ||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Stra[NCT02959255] | Phase 4 | 364 participants (Actual) | Interventional | 2017-01-30 | Completed | ||
| Randomized, Controlled, Multicenter Phase III Study for the Efficacy and Tolerability of Triple Therapy With Esomeprazole, Moxifloxacin and Amoxicillin for Rescue Therapy of Helicobacter Pylori Infection[NCT00455806] | Phase 3 | 132 participants | Interventional | 2007-01-31 | Recruiting | ||
| Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection[NCT00656968] | Phase 4 | 232 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori) (NCT02547038)
Timeframe: sixth week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 169 |
| (Panto+Amox+Clar+Metr)+(Panto+Amox) | 170 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
Number of participants with negative H pylori status in follow-up tests as a measure of successful eradication (NCT02978157)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo | 36 |
| Esomeprazole+Bismuth+Tetra+Levo | 49 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT00656968)
Timeframe: one month after finishing study drugs
| Intervention | participants (Number) |
|---|---|
| Concomitant Therapy (A) | 92 |
| Sequential Therapy (B) | 95 |
Good drug compliance is defined as taking equal to or more than 80% of eradication medicines (NCT00656968)
Timeframe: one month after finishing test therapy
| Intervention | participants (Number) |
|---|---|
| Concomitant Therapy (A) | 106 |
| Sequential Therapy (B) | 104 |
17 reviews available for tinidazole and Infections, Helicobacter
| Article | Year |
|---|---|
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administration Schedul | 2018 |
Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?
Topics: Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Communicab | 2014 |
Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration | 2009 |
[Tinidazole: a classical anaerobical drug with multiple potential uses nowadays].
Topics: Anaerobiosis; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antiprotozoal Agents; Bacteria | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
[Eradication of Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Enzym | 2003 |
Tinidazole: from protozoa to Helicobacter pylori--the past, present and future of a nitroimidazole with peculiarities.
Topics: Amebiasis; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antitrichomonal Agents; Clinical | 2004 |
[Treatment for Helicobacter pylori: current criteria].
Topics: Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug A | 2007 |
Treatment strategies for symptom resolution, healing, and Helicobacter pylori eradication in duodenal ulcer patients.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; | 1994 |
Effect of lansoprazole on Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Drug Therapy, Combination; Dyspepsia; Helicoba | 1993 |
Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment.
Topics: Amoxicillin; Bismuth; Cimetidine; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter | 1993 |
Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combin | 1996 |
[Helicobacter pylori eradication: triple therapy versus dual therapy].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Com | 1996 |
Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.
Topics: Amoxicillin; Antitrichomonal Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Com | 1997 |
Guidelines for the treatment of Helicobacter pylori in the pediatric population.
Topics: Adolescent; Amoxicillin; Bismuth; Child; Child, Preschool; Drug Therapy, Combination; Duodenal Ulcer | 1997 |
Therapy of H. pylori infection.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Clarithromycin; | 1997 |
126 trials available for tinidazole and Infections, Helicobacter
| Article | Year |
|---|---|
Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability.
Topics: Amoxicillin; Clarithromycin; Drug Costs; Drug Therapy, Combination; Gastritis; Helicobacter Infectio | 2020 |
Comparing the Efficacy of Sequential and Standard Quadruple Therapy for Eradication of H. Pylori Infection.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections | 2020 |
Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Esomepra | 2021 |
Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial.
Topics: Adult; Amoxicillin; Clarithromycin; Dysgeusia; Esomeprazole; Female; Gastritis; Helicobacter Infecti | 2018 |
Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Clarithromycin; Drug Administration Sched | 2019 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alkylating Agents; Amoxicillin; Anti-Bacterial Agent | 2013 |
A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; China; | 2014 |
Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment: comparison between two tetracycline-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Drug Resistance, Bacterial; Dru | 2014 |
Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2015 |
Effect of Helicobacter pylori eradication on reflux esophagitis therapy: a multi-center randomized control study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Esomeprazole; Esophagitis, Peptic; Female; Gastroesophageal Re | 2015 |
Helicobacter pylori eradication: metronidazole or tinidazole? Data from Turin, Italy.
Topics: Anti-Infective Agents; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Me | 2008 |
The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Clarithromycin; Double-Blind Method; | 2009 |
Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 2010 |
Sequential therapy compared with standard triple therapy for Helicobacter pylori eradication in children: a double-blind, randomized, controlled trial.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Double-Bli | 2011 |
Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Ammonia; Anti-Bacterial Agents; Clarithromycin; Drug | 2011 |
High eradication rates of Helicobacter pylori infection following sequential therapy: the Israeli experience treating naïve patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; | 2011 |
Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dr | 2012 |
Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti | 2012 |
Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2013 |
Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dru | 2013 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
Omeprazole plus azithromycin and either amoxicillin or tinidazole for eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Azithromycin; Dose-Response Relationship, Drug; Drug Administration Schedu | 2003 |
Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial.
Topics: Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combin | 2003 |
Diagnosis and eradication of Helicobacter pylori in patients with duodenal ulceration in the community.
Topics: Adult; Aged; Anti-Bacterial Agents; Breath Tests; Drug Therapy, Combination; Duodenal Ulcer; Female; | 2003 |
Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal A | 2003 |
Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 2003 |
Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Benz | 2003 |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2003 |
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bac | 2003 |
Use of bovine lactoferrin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitric | 2003 |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Rank order of success favors longer duration of imidazole-based therapy for Helicobacter pylori in duodenal ulcer disease: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2004 |
Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benz | 2004 |
Helicobacter pylori eradication: efficacy of conventional therapy in India.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Clarithromycin; Double-Blin | 2004 |
Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2004 |
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 2004 |
Dual vs. triple therapy for childhood Helicobacter pylori gastritis: a double-blind randomized multicentre trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Breath Tests; Child; Double-Blind | 2004 |
Helicobacter pylori eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Azithromycin; Breath Tests; Child; Doubl | 2004 |
Lewis and Secretor status and Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Helicobacte | 2004 |
Comparison of one week and two weeks of triple therapy for the eradication of Helicobacter pylori in a Sri Lankan population: a randomised, controlled study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analysis of Variance; Clarithromycin; Confidence Inte | 2004 |
Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Aza Compounds; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Fluor | 2005 |
Long-term follow-up after eradication of Helicobacter pylori with omeprazole, clarithromycin, and tinidazole (OCT regimen) in a Japanese population.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combina | 2005 |
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal | 2005 |
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal | 2005 |
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal | 2005 |
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal | 2005 |
A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Antitrichomon | 2006 |
Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin | 2006 |
Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2006 |
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Cattle; Chi-Square Distribution; Cla | 2006 |
Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal A | 2006 |
Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2006 |
Oral health status and oral hygiene practices of patients with peptic ulcer and how these affect Helicobacter pylori eradication from the stomach.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2007 |
Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Endoscopy, Gastrointestinal; | 2007 |
Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2007 |
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use.
Topics: Adult; Alkylating Agents; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Ana | 2007 |
Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized
Topics: Adult; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer | 1995 |
Antibiotic versus maintenance therapy in the prevention of duodenal ulcer recurrence. Results of a multicentric double-blind randomized trial.
Topics: Adult; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Fema | 1995 |
Triple therapy with sucralfate is not effective in eradicating Helicobacter pylori and does not reduce duodenal ulcer relapse rates.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up St | 1994 |
Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duode | 1993 |
Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Resistance, Micr | 1995 |
Prevention and treatment of low-grade B-cell primary gastric lymphoma by anti-H. pylori therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Antitrichomonal Agents; Drug Therapy, Combination; Female; Hel | 1995 |
The use of azithromycin in short-term low-dose triple therapies for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Therapy, Combination; Heli | 1996 |
Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Dru | 1996 |
One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1996 |
Cure of gastric ulcer disease after cure of Helicobacter pylori infection--German Gastric Ulcer Study.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Bismuth; Drug Administration Schedule; Drug The | 1996 |
Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, | 1996 |
Omeprazole versus ranitidine: short-term triple-therapy in patients with Helicobacter pylori-positive duodenal ulcers.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Chi-Square Distributi | 1996 |
One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Admin | 1996 |
Ranitidine in a twice daily triple-therapy regimen for the eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Com | 1996 |
Evaluation of the efficacy and tolerability of four different therapeutic regimens for the Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 1996 |
One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Microbial; Drug Therap | 1997 |
Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Com | 1997 |
Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Follow- | 1997 |
Helicobacter pylori, efficacy of the new triple therapy in six and twelve-day schedules.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; | 1997 |
Family treatment of symptomatic children with Helicobacter pylori infection.
Topics: Adolescent; Adult; Amoxicillin; Carrier State; Child; Child, Preschool; Chronic Disease; Disease Tra | 1997 |
A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
Effects of Helicobacter pylori eradication on gastric function indices in functional dyspepsia. A prospective controlled study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsi | 1998 |
One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Administrat | 1998 |
Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Bli | 1998 |
Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Admin | 1998 |
Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1998 |
One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double- | 1998 |
[Eradication therapies for Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Fe | 1998 |
Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Clarithromycin; | 1998 |
Evaluation of a new ultrashort triple therapy for Helicobacter pylori disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Azithromycin; Female; Helic | 1998 |
Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Chlamydia Infections; Chlamydophila pneumoniae; Chronic Di | 1999 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Clarithr | 1999 |
Seven days of ranitidine bismuth citrate plus two antimicrobials for Helicobacter pylori eradication.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Confidence Intervals; Drug Administration Schedule; Dr | 1999 |
Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithro | 1999 |
Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; | 1999 |
Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug T | 2000 |
Efficacy of a multistep strategy for Helicobacter pylori eradication.
Topics: Algorithms; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Res | 2000 |
Four-day, twice daily, quadruple therapy with amoxicillin, clarithromycin, tinidazole and omeprazole to cure Helicobacter pylori infection: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diarrhea; Drug A | 2000 |
One week triple therapy for Helicobacter pylori associated duodenal ulcer disease.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichom | 1999 |
Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Bism | 2000 |
Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antitrichomona | 2000 |
A new highly effective short-term therapy schedule for Helicobacter pylori eradication.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitricho | 2000 |
The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clari | 2000 |
Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group.
Topics: Adult; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; | 2000 |
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; | 2000 |
In dyspeptic patients without gastric phase III of the migrating motor complex, Helicobacter pylori eradication produces no short-term changes in interdigestive motility pattern.
Topics: Administration, Oral; Adult; Analysis of Variance; Biopsy, Needle; Breath Tests; Clarithromycin; Dru | 2000 |
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2000 |
Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Azithromycin; Benzimidazoles; Drug Therapy, Co | 2000 |
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infe | 2000 |
Helicobacter pylori infection in childhood: results of management with ranitidine bismuth citrate plus amoxicillin and tinidazole.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Drug Therapy, Com | 2000 |
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 2001 |
Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies | 2001 |
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2001 |
Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Dr | 2000 |
Limited usefulness of a seven-day twice-a-day quadruple therapy.
Topics: Adult; Aged; Amoxicillin; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administratio | 2000 |
Comparison of two regimens on eradication of Helicobacter pylori.
Topics: Amoxicillin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Th | 2000 |
[The effect of cigarette smoking and alcohol consumption on efficacy of Helicobacter pylori eradication].
Topics: Adult; Alcohol Drinking; Amoxicillin; Clarithromycin; Comorbidity; Drug Therapy, Combination; Female | 2000 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarit | 2001 |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacter | 2001 |
A triple therapy regimen after failed Helicobacter pylori treatments.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Biopsy; Bismuth; Brea | 2001 |
Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combin | 2001 |
Efficacy of a nitroimidazole containing tripletherapy regime in Singapore.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clar | 2001 |
Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease.
Topics: Adult; Aged; Clarithromycin; Double-Blind Method; Female; Gastroesophageal Reflux; Helicobacter Infe | 2001 |
Two new treatment regimens for Helicobacter pylori eradication: a randomised study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; | 2001 |
Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Breath T | 2002 |
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Dyspepsia; Female; Health Care | 2002 |
Mono and dual therapy for Helicobacter pylori associated gastritis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; G | 1991 |
Duodenal ulcer relapse after eradication of Helicobacter pylori.
Topics: Amoxicillin; Antacids; Bismuth; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Helicoba | 1991 |
62 other studies available for tinidazole and Infections, Helicobacter
| Article | Year |
|---|---|
Clinical Effect of Clarithromycin Combined with Tinidazole on Helicobacter pylori-Related Gastritis and Its Influence on COX-2 Expression.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cyclooxygenase 2; Drug Therapy, Combinati | 2021 |
RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Drug Th | 2022 |
Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Resistance, Bacterial; Fosfomy | 2022 |
Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration S | 2018 |
[Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment].
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Furazolidone | 2018 |
How and when investigating and treating Helicobacter pylori infection in children.
Topics: Amoxicillin; Anti-Bacterial Agents; Biopsy; Child; Child, Preschool; Clarithromycin; Drug Resistance | 2018 |
Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Clarithromycin; Cytochrome | 2019 |
Does standard triple therapy still have a role in first-line Helicobacter pylori eradication in Korea?
Topics: Amoxicillin; Clarithromycin; Communicable Disease Control; Disease Eradication; Drug Resistance, Bac | 2014 |
Seminal Helicobacter pylori treatment improves sperm motility in infertile asthenozoospermic men.
Topics: Adult; Antibodies, Bacterial; Asthenozoospermia; Clarithromycin; Cohort Studies; Confidence Interval | 2014 |
Simultaneous determination of triple therapy for Helicobacter pylori in human plasma by reversed phase chromatography with online wavelength switching.
Topics: Administration, Oral; Anti-Bacterial Agents; Blood Chemical Analysis; Chromatography, Reverse-Phase; | 2015 |
Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2015 |
Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2017 |
Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians.
Topics: Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxyla | 2009 |
Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Doxycyc | 2010 |
Sequential or concomitant therapy for Helicobacter pylori eradication?
Topics: Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infecti | 2010 |
Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication?
Topics: Adolescent; Adult; Aged; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; | 2010 |
Efficacy, tolerability, and factors affecting the efficacy of the sequential therapy in curing Helicobacter pylori infection in clinical setting.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Endoscopy; Female; Helicobacter | 2011 |
Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Breath Tests; Clarithromycin; Comorbidity; | 2012 |
Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
Triple eradication therapy counteracts functional impairment associated with Helicobacter pylori infection in Mongolian gerbils.
Topics: Amoxicillin; Animals; Anti-Ulcer Agents; Colony Count, Microbial; Drug Therapy, Combination; Gastric | 2003 |
[Failure of Helicobacter pylori eradication--suggestions for further therapy].
Topics: Age Distribution; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bac | 2003 |
Efficacy of the triple therapy: proton pomp inhibitors, amoxicillin and tynidazole in Helicobacter pylori infection treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; | 2002 |
Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Antitrichomonal Agen | 2003 |
Lactoferrin: milking ulcers?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cattle; Clarithromycin; Drug Thera | 2003 |
Effect of antibacterial therapy and salivary secretion on the efficacy of Helicobacter pylori eradication in duodenal ulcer patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; | 2004 |
Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitrichomonal Agents; Clarithromycin; Drug | 2005 |
Effect of probiotics and triple eradication therapy on the cyclooxygenase (COX)-2 expression, apoptosis, and functional gastric mucosal impairment in Helicobacter pylori-infected Mongolian gerbils.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Apoptosis; bcl-2-Associated X Protein; Cyclooxygenase 2 | 2006 |
Prevalence and treatment of Helicobacter pylori in patients with blepharitis.
Topics: Adult; Anti-Bacterial Agents; Blepharitis; Breath Tests; Chronic Disease; Drug Therapy, Combination; | 2006 |
Failure of sequential therapy to eradicate Helicobacter pylori in previously treated subjects.
Topics: Adolescent; Adult; Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Enz | 2007 |
Endoscopic patterns and histopathological features after eradication therapy in Helicobacter pylori-associated nodular gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alkylating Agents; Amoxicillin; Anti-Bacterial Agent | 2008 |
Effect of H pylori infection and its eradication on hyperammo-nemia and hepatic encephalopathy in cirrhotic patients.
Topics: Adult; Aged; Alkylating Agents; Anti-Bacterial Agents; Anti-Ulcer Agents; China; Clarithromycin; Fem | 2008 |
[Helicobacter heilmannii: new spiral shaped bacterium that may be responsible for ulcerated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Amoxicillin; Anti-Ulcer Agents; Drug Therapy | 1995 |
Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers.
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1995 |
One-week low-dose triple therapy: new standards for Helicobacter pylori treatment.
Topics: Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; He | 1995 |
Helicobacter pylori gastritis in dyspeptic children. A long-term follow-up after treatment with colloidal bismuth subcitrate and tinidazole.
Topics: Adolescent; Biomarkers; Child; Child, Preschool; Drug Therapy, Combination; Dyspepsia; Female; Follo | 1994 |
[Helicobacter pylori gastritis manifested by acute anemia].
Topics: Acute Disease; Amoxicillin; Anemia; Antibodies, Bacterial; Child; Drug Therapy, Combination; Endosco | 1993 |
Helicobacter pylori-associated gastritis in Kuwait: endoscopy-based study in symptomatic and asymptomatic children.
Topics: Abdominal Pain; Administration, Oral; Adolescent; Amoxicillin; Biopsy; Child; Child, Preschool; Duod | 1993 |
Italian omeprazole triple therapy--a 1-week regimen.
Topics: Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter | 1996 |
The Helicobacter felis mouse model in assessing anti-Helicobacter therapies and gastric mucosal prostaglandin E2 levels.
Topics: Amoxicillin; Animals; Anti-Ulcer Agents; Catechols; Dinoprostone; Disease Models, Animal; Drug Thera | 1996 |
High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Cl | 1996 |
Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1996 |
Helicobacter pylori reinfection is rare in peptic ulcer patients cured by antimicrobial therapy.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-U | 1996 |
Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.
Topics: Adult; Age Factors; Aged; Alcohol Drinking; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 1997 |
Urticaria during triple therapy for Helicobacter pylori infection: clinical implications.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Eruptions; Drug Therapy, Combination; Fe | 1997 |
Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Resist | 1996 |
[Short-term (6 days) eradication of Helicobacter pylori infection in the practice of a health insurance physician].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Azithromycin; Benzimidazoles; Female; He | 1998 |
[Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1997 |
Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; F | 1998 |
Weekend therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Sc | 1998 |
Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; D | 1998 |
Use of a urea breath test to evaluate short-term treatments for cats naturally infected with Helicobacter heilmannii.
Topics: Animals; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Azithromycin; B | 1999 |
The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chile; Developing Countries; Drug Therapy, | 2000 |
Remission of a high-grade gastric mucosa associated lymphoid tissue (MALT) lymphoma following Helicobacter pylori eradication and highly active antiretroviral therapy in a patient with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Age | 2001 |
Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bangladesh; Body Mass Index; Breath Tests; Carbon Isotopes; D | 2001 |
[Pharmacotherapeutic aspects of early postoperative period in patients with complicated gastroduodenal ulcer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitrichomonal Agents; Clarithro | 2002 |
Quantitative assessment of histological changes in chronic gastritis after eradication of Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Chronic Disease; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastros | 1992 |
Clinicopathological assessment of gastric biopsy samples of patients with Helicobacter pylori infection--metronidazole resistance and compliance problems in the United Arab Emirates.
Topics: Adolescent; Adult; Antacids; Bacteriological Techniques; Bismuth; Doxycycline; Drug Resistance, Micr | 1992 |
Eighteen month follow up of Helicobacter pylori positive children treated with amoxycillin and tinidazole.
Topics: Adolescent; Amoxicillin; Child; Child, Preschool; Drug Therapy, Combination; Dyspepsia; Female; Foll | 1992 |
Dental plaque: a permanent reservoir of Helicobacter pylori?
Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Dental Plaque; Doxycycline; Drug Therapy, Combinatio | 1991 |
Epidemiology and treatment of gastric Campylobacter pylori infection: more questions than answers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Diagnosis, Differential; Drug Ther | 1990 |